After Hours Watch List Scorecard: MDVN, EGLE, PRGS, SLW (NASDAQ:MDVN)

After Hours Watch List Scorecard: MDVN, EGLE, PRGS, SLW (NASDAQ:MDVN)

The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of

(Visited 2 times, 1 visits today)
4
Like
Save

Comments

Write a comment

*